4 studies found for:    18156031 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Alternative Dosing for CRLX101 Alone and With Avastin in Advanced Solid Tumors
Condition: Solid Tumors
Interventions: Drug: CRLX101;   Drug: Bevacizumab
2 Active, not recruiting Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma
Conditions: Carcinoma;   Carcinoma Renal Cell;   Kidney Neoplasms;   Kidney Diseases;   Chemokines
Intervention: Biological: Biological sample
3 Completed Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors
Conditions: Metastatic Renal Cell Carcinoma;   Advanced Refractory Solid Tumors Histologically or Cytologically Confirmed
Intervention: Drug: Association of Bevacizumab (BVC)+ Pazopanib (PZP)
4 Completed A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies
Conditions: Renal Cell Carcinoma;   Breast Cancer;   Colon Cancer;   Lung Cancer;   Non-Hodgkin Lymphoma
Intervention: Drug: dimethane sulfonate (DMS612, NSC 281612)

Indicates status has not been verified in more than two years